This session reviews how epigenetic deregulation contributes to the development of hematological malignancies, with a focus on myeloid malignancies.
Epigenetics in Malignant Hematology
Maria E. Figueroa, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL,
USA
Objectives:
- To recognize epigenetic modifiers that contribute to malignant transformation.
- To recognize the amplifying effect of epigenetic mutations by reprogramming the epigenome.
Recording Date: November 16, 2020
Continuing Education Credit Information
CME/CMLE credit: 1.00 hr
Last day to purchase course and CE claim credit: February 16, 2024
Note: Members of AMP can access this at a discount. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
